RACL Geartech Q1FY27: revenue +31% YoY, PAT growth capped at +8% by tax-rate spike
PAT +7.75% YoY · revenue +31.5% · margins expanding
₹132.35 Cr
+31.5% YoY
₹8.9 Cr
+7.75% YoY
6.71%
-0.9pp YoY
₹7.55
RACL Geartech's consolidated revenue came in at ₹132.35 Cr, up 31.5% YoY (₹100.65 Cr) and roughly flat QoQ (₹131.66 Cr, +0.5%). Consolidated PBT rose faster still, up 49.4% YoY to ₹16.82 Cr, but consolidated PAT of ₹8.90 Cr grew just 7.75% YoY (and fell 27.9% QoQ from ₹12.35 Cr). EPS was ₹7.55 versus ₹7.01 a year ago. Standalone tracked closely — revenue ₹127.63 Cr, PAT ₹8.77 Cr (+5.8% YoY), EPS ₹7.44 — with the German subsidiary contributing ₹8.19 Cr of revenue and ₹3.11 Cr of PAT to the consolidated group number.
Q1 FY-2027 vs prior quarters
The gap between strong topline/PBT growth and muted PAT growth is explained below the operating line, not by weaker manufacturing performance. Operating margin actually expanded to an estimated ~24.1% of revenue from ~18.7% a year ago and ~22.2% last quarter, consistent with the 31.5% volume/revenue growth flowing through. But two non-operating items suppressed the reported bottom line: other income collapsed to ₹0.25 Cr from ₹8.05 Cr in the year-ago quarter (removing a large favourable prior-year base), and the effective tax rate jumped to ~47% (₹7.92 Cr tax on ₹16.82 Cr PBT) versus a normalised ~27% in the preceding two comparable quarters, driven by a ₹3.14 Cr deferred-tax charge the filing does not itemise. Net profit margin consequently fell to 6.7% from 7.6% YoY and 9.0% QoQ — an optical compression rather than a core-margin one.
The stock went into the print at ₹1,482.7, up 17.8% over the past month of trading.
Management provided a robust outlook, projecting continued growth with revenue expected to exceed 565 crores plus or minus 5% for FY27. The company is strategically investing in high-growth segments like electric vehicles and premium motorcycle applications, evidenced by new customer wins and ongoing project developmen
— This quarter: beat
Management's FY27 guidance from the Q4FY26 call calls for consolidated revenue above ₹565 Cr (±5%), roughly 10% growth over FY26's ₹512.42 Cr; this quarter's 31.5% YoY pace is running well ahead of that trajectory, though a single quarter does not confirm the full-year number. No sell-side estimates for this print were found — RACL Geartech carries no visible brokerage coverage — so the result cannot be graded against street consensus. Exports remained the core engine: Germany (₹38.69 Cr) and Austria (₹34.07 Cr) together drove the bulk of ₹86.95 Cr in export revenue (66% of the total), against ₹45.40 Cr domestic. The filing carries no accompanying management press release or commentary. Alongside the results, the board re-appointed Gursharan Singh as Chairman & Managing Director for a fresh five-year term (August 2027–August 2032) and fixed the 43rd AGM for September 14, 2026 — routine governance items unrelated to the quarter's numbers.
W1
Effective tax rate: whether the ~47% rate (vs ~27% normalised, ₹3.14 Cr deferred-tax charge) reverses next quarter — normalisation would materially lift reported PAT growth.
W2
Other income run-rate: whether ₹0.25 Cr (down from ₹8.05 Cr in Q1FY26) persists or last year's level was itself a one-off, which sets the true YoY PAT comparison base ahead.
W3
FY27 guidance (>₹565 Cr ±5%): Q1 revenue of ₹132.35 Cr implies ~₹432 Cr needed over the remaining three quarters — track whether the +31.5% YoY pace holds or moderates.
Consolidated statement header is mislabeled 'AUDITED' (template carryover) but body text and the board outcome letter confirm both statements are un-audited with limited review; effective tax rate jumped to ~47% (₹3.14 Cr deferred tax charge, unexplained in filing) vs ~27% normalised in the two comparable quarters; year-ago quarter carried unusually high other income (₹8.05 Cr) vs ₹0.25 Cr now, distorting YoY PAT comparability; no exceptional items in either compared period so no formal adjusted-PAT figure applies; wholly-owned subsidiary RACL Geartech GmbH added ₹8.19 Cr revenue/₹3.11 Cr PAT to consolidated.
Strong YoY growth masks Q1 flatness; new programs ramping cautiously
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met 500 Cr FY26 target; on track for 565±5% FY27 guidance. New programs progressing as outlined, but no upside surprise evident.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong YoY revenue (31.5%) masks sequential stall (+0.5%) and PAT weakness (7.7% vs revenue growth). New catalysts (BMW, Royal Enfield, KTM recovery) are real but ramping cautiously; management deliberately held guidance despite tailwinds, signaling measured confidence. Multi-supplier risk on Royal Enfield and execution risk on adjacent verticals (aerospace, robotics) are material.
₹132.3 Cr
Revenue · +31.5% YoY₹8.9 Cr
Reported PAT · +7.7% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
KTM has bounced back to pre-COVID levels
METManagement claims recovery but no revenue breakout shown; KTM contribution not quantified in this quarter
Royal Enfield is a very big domestic order
OVERSTATED10,000 sets/month nominated, currently sustaining 7.5-8,000 units/month; 8 months into ramp, still sub-scale
BMW Project Venus SOP on track for October 2026
METLevel 1 approval done, final approval scheduled Oct 24, pilot supplies already started
Coming times showing very encouraging outlook
MISSQoQ revenue +0.5%, PAT -27.9% QoQ; management did NOT upgrade FY27 guidance despite new catalysts
Maintaining EBITDA margin of ~24%
METQ1 OPM reported at 24.1%; consistent with prior year 24.1%
Earnings quality
What changed since the last call
KTM revenue stabilizing vs prior concern
UpgradePrior call: KTM in recovery mode post-insolvency. Q1 call: 'Bounced back, pre-COVID levels or slightly above, new Duke 790 launching, good forecast.' Narrative upgraded but no hard numbers shared.
Royal Enfield empanelment announced, scaling production
NewJanuary 2026 commercial supplies began; 10,000 sets/month nominated (350 CC motorcycle). Currently sustaining 7.5-8,000. Multi-supplier, confidential scale withheld by management.
BMW Project Venus accelerating approvals
UpgradePrior: Project underway, approvals pending. Q1: Level 1 approval granted, final approval Oct 24, pilot supplies started. Incremental de-risking.
FY27 guidance NOT revised upward
NeutralDespite KTM recovery, Royal Enfield win, BMW acceleration, management explicitly held 565±5% guidance. Rationale: customers not growing >20%, RACL share <20% per customer, mid-year guidance changes inappropriate.
Capex disclosed; heat treatment replacement underway
Neutral₹77.4 Cr capex: ₹40 Cr heat treatment plant replacement (foundation Jan, commissioning Jan 27), ₹35 Cr capacity expansion. Strategic but capital-intensive; no acceleration vs plan.
The Q&A
Moderate. Analysts pressed on guidance revision (Shashank Kanodia, Abhisar Jain), Royal Enfield scale and market share (Jainam Madrecha), ZF trajectory (Prabh answered directly). Management stood firm: not upgrading mid-year, withheld Royal Enfield volume % citing competitive risk, and emphasized incubation strategy for new verticals. Tone was measured, not defensive; management held their line on cautious execution.
KTM recovery trajectory — Sid
AnsweredKTM Austria bounced back to pre-COVID; RACL's Austrian subsidiary serves KTM. Bajaj India multi-sourcing strategy ongoing; RACL already supplies Royal Enfield, TVS. New opportunities with Bajaj over time.
BMW SOP status — Piyush Jain
AnsweredLevel 1 approval done, conditional shipments started, final approval Oct 24. Pilot supplies moving to customer cars now. Everything on track, no delays.
Royal Enfield details — Piyush Jain
Partial350 CC model, 10,000 sets/month nominated, currently 7.5-8,000 sustaining. Other new models under confidentiality. Competitive sensitivity; won't disclose %. Sizable business.
ZF business trajectory — Piyush Jain
AnsweredPrior sluggishness due to OEM car models. X5 platform now active, 50-60% utilization. Peak revenue shifted 2028→2030. Electric power steering project ramping end-2027/mid-2028 for American OEM; another big opportunity.
Non-auto diversification — Abhisar Jain
AnsweredAerospace/civil aviation (Airbus focus), actuators/micromotors, robotics (high demand but early stage, few Indian players). Incubation strategy: test, then scale. Will update investors in 1-2 years.
Guidance revision possibility — Shashank Kanodia
DodgedGuidance given once yearly. Even if customer grows 50-60%, RACL's share <20% per customer. Wouldn't revise mid-year. Will perform within 565±5% benchmark; possible upside but no formal change.
EBITDA margin sustainability — Shashank Kanodia
PartialShould be happy accepting these margins, maintained long-term. Nothing stationary; 2% variance quarter-to-quarter normal. Aspiration is to maintain baseline profitability.
Tax rate outlook — Shashank Kanodia
AnsweredBlended FY27 tax rate: 25.62%. Q1 elevated due to surcharge rate change in deferred tax calculation. This was explained in profitability slide.
Royal Enfield outsourcing pattern — Nisarg Shah
AnsweredYes. OEMs want to focus on assembly (commanding position). Supply chain maturity in India now allows this. RACL single-source for export; domestic OEMs multi-source. Creating niche in premium segment.
Precision manufacturing barriers — Nisarg Shah
AnsweredNot making; it's consistency at scale. Process capability, traceability, people/technology to produce 100K+ parts/month reliably. Customers won't take risk; RACL A-rated supplier = support.
Royal Enfield capacity planning — Jainam Madrecha
AnsweredMulti-supplier customer; we invest cautiously. First prove demand sustainable long-term, then add capacity. No idle capacity; won't jump on demand spikes. Deliberate ramp-up.
Product lifecycle turnover — Jainam Madrecha
AnsweredNo major end-of-life products today. One project ending but successor model (higher value-add) replacing it. Every 2-3 years add new customer, existing customers add new models.
BMW sole-source confirmation — Jainam Madrecha
AnsweredYes. Export business model: sole source per component until EOL. Global OEM strategy (supply chain risk in field). Domestic (multi-supplier) is different.
ZF competitive leverage — Bhargav Buddhadev
AnsweredLarge ZF portal RFQ system (no human intervention). Buyers globally upload requirements; RACL marketing monitors, bids if suitable. Automatic discovery; no lobbying needed.
Risk mitigation on project failures — Bhargav Buddhadev
AnsweredYes, indirectly. Customers support suppliers through cost increases, alternative business, or cash if model fails. Depends on relationship strength (A-rated vs C-rated). RACL is A-rated.
RFQ surge from Europe — Bhargav Buddhadev
AnsweredTrue, witnessing RFQ spike. Many are RFIs (requests for information) not firm RFQs. Geopolitical rebalancing real; supply chains being rewritten. Cautious optimism. Will pursue opportunity.
Capex for next 3 years — Adi
PartialThis year ₹77.4 Cr disclosed. Next year's capex will come in January. Beyond 2028-29, too early. Gear business capital-intensive; regular capex needed for growth.
5-year growth ambition & M&A — Adi
Answered15-20% annual growth, target to double revenue in 3-4 years. Non-auto opportunities (aerospace, actuators, robotics, defense) identified. Incubation model; no aggressive M&A planned yet.
Guidance
FY27 revenue ~570 Cr (±5%, = 541.5-598.5 Cr)
HighGuidance reaffirmed, not revised upward. Management explained: customers not growing >20%, RACL <20% per customer, mid-year revisions not appropriate. Q1 run-rate suggests 529 Cr annualized (below mid-point); FY27 will need Q2-Q4 acceleration.
EBITDA margin ~24.1%, maintained
HighQ1 delivered 24.1%; management aspires to maintain. Acknowledged 2% variance normal quarter-to-quarter. No margin expansion target.
FY27 capex ₹77.4 Cr (₹40 Cr heat treatment replacement + ₹35 Cr capacity)
HighFoundation laid Jan 26, building completion Oct 26, equipment arrival Sept-Oct, commissioning Oct-Dec, trial production Jan 27. Replacement is non-discretionary; expansion tied to customer ramps.
Risks the call surfaced
Customer concentration
Medium29 active customers is diversified, but loss of major customer (BMW, Royal Enfield, KTM, ZF) would be material. Royal Enfield multi-supplier adds risk.
Royal Enfield execution
Medium10,000 units/month nominated; currently 7.5-8,000. Multi-supplier model means RACL could lose share if costs rise or alternative suppliers qualify. Domestic market highly price-sensitive per management.
Sequential revenue weakness
MediumQoQ revenue +0.5% despite 31.5% YoY growth signals Q1 weakness or customer order lumps. PAT -27.9% QoQ is sharp; tax impact (surcharge rate change) cited but underlying margin may be under pressure.
Capex execution and debt
Medium₹77.4 Cr capex in FY27 (14% of annual revenue) is significant. Heat treatment plant on schedule but equipment delivery Sept-Oct critical path; delays post-commissioning (Jan 27) would impact expansion timeline and ROI.
Long-term adjacency execution
LowManagement mentioned aerospace (Airbus), robotics, actuators, industrial components as 2-3 year opportunities, but no revenue materialization and execution unknown. Distracts capex and management attention without current business impact.
Management
Score 7/10. Clear and structured. Transparent on challenges (energy crisis, geopolitical risks), catalysts (BMW, Royal Enfield, KTM recovery), and constraints (no mid-year guidance revision). Withheld some competitive details (Royal Enfield volume %, pricing) citing risk; reasonable but limits transparency. Strong track record. Met 500 Cr FY26 target, on track for 565±5% FY27. Heat treatment plant capex execution on timeline (foundation Jan, commissioning Jan 27 on track). New customer wins (BMW, Royal Enfield) progressing but still ramping; not yet transformative.
1 · Oct 24, 2026
BMW Project Venus final approval sign-off; pilot supplies ongoing
2 · Dec 2026
Heat treatment plant commissioning (foundation laid Jan 26); switch from LPG to electric
3 · Jan 2027
Heat treatment plant trial production; capex cycle easing post-commissioning
Multi-supplier risk on Royal Enfield and execution risk on adjacent verticals (aerospace, robotics) are material.
31% growth masks 0.5% quarter — RACL holds the line on guidance
Reported revenue surged 31.5% year-over-year, but grew just 0.5% sequentially. The street's initial reaction (−6.4% day 1) was to look past the headline and question momentum—a reading management's refusal to raise full-year guidance has quietly confirmed.
The numbers: a split verdict
31.5%
₹132.3 Cr vs ₹100.6 Cr last year
0.5%
₹132.3 Cr vs ~₹131.9 Cr prior quarter
7.7%
₹8.9 Cr; lags revenue growth significantly
24.1%
Flat year-over-year; stable
The headline tells one story: 31.5% year-over-year revenue growth, the kind of number that shows up in investor presentations as proof of momentum. But the quarter itself tells another. Sequential growth of just 0.5%—near-flat—combined with net profit down 27.9% quarter-over-quarter, signals that Q1 was a weak quarter inside a strong year. The market saw it first: the stock fell 6.4% on day 1 of the announcement and held losses through day 5 (−6.25%), a verdict that tracked with management's own caution.
Why the PAT growth lags revenue so sharply
Profit grew 7.7% while revenue grew 31.5%. Three factors explain the gap. First: tax. Q1 tax rate was 47%, well above the full-year target of 25.62%, due to a surcharge rate change affecting deferred tax calculations—a one-time impact that depressed reported PAT by roughly ₹1–2 Cr. Second: cost inflation. Raw materials are reflected at 28% of revenue, but this includes a stock-in-transit timing benefit; historical RM ran 30–33%, suggesting underlying cost pressure. Third: operating expense absorption, which may not have scaled proportionally with revenue. The upshot: organic profit growth is materially softer than the headline 7.7% suggests.
What management claimed vs. what holds up
KTM has bounced back to pre-COVID levels; recovery is real
No revenue breakout disclosed for KTM in Q1. New Duke 790 launching, management 'confident' in forecast, but contribution not quantified.
Supported (narrative), not validated (numbers)
Royal Enfield is a very big domestic order with potential to scale
10,000 sets/month nominated; currently sustaining 7.5–8,000 units/month. Eight months into commercial supplies (Jan 2026 start), still sub-scale.
Slightly overstated (ramp slower than OEM target)
BMW Project Venus SOP on track for October 2026; pilot supplies started
Level 1 approval done. Final approval scheduled Oct 24. Pilot supplies already shipped to customer cars. Zero delays reported.
Fully supported
Coming times show very encouraging outlook; expect continued growth
QoQ revenue +0.5%, PAT −27.9% QoQ. Management held FY27 guidance at 565±5% Cr despite multiple catalysts (KTM, RE, BMW). No upgrade.
Contradicted (actions speak louder)
Maintaining EBITDA margins of ~24%
Q1 OPM reported at 24.1%; consistent with prior-year 24.1%. Within expected range.
Fully supported
What changed: new wins, held guidance
Three material updates from the call. First: KTM recovery confirmed. The Austrian subsidiary's customer, KTM Bikes, has stabilized post-insolvency. New models (Duke 790, etc.) are launching; management flagged 'good forecast' for coming months. No revenue uplift visible in Q1, but narrative upgraded from 'in recovery' to 'bounced back to pre-COVID levels or slightly above.' Second: Royal Enfield empanelment progressing. Commercial supplies began in January 2026 for a 350 CC motorcycle transmission. Current run-rate is 7.5–8,000 units/month; target is 10,000/month. Multi-model pipeline under development (confidential). Third: BMW Project Venus de-risked. Level 1 approval complete, pilot supplies in transit or already at customer; final approvals scheduled for October 24. This is the company's sole-source opportunity on a major OEM platform.
Guidance held despite all three catalysts. Analysts asked repeatedly whether KTM + Royal Enfield + BMW warranted an upward revision to FY27 guidance (currently 565±5% Cr). Management declined and explicitly held the range. Rationale offered: customers not growing >20% organically, RACL's share <20% per customer, and mid-year revisions 'inappropriate.' This restraint is credible, but it is also a subtle signal that management lacks visibility into these ramps accelerating materially in FY27. Expect Q2–Q4 to need significant acceleration to hit the mid-point.
Earnings quality: three red flags
Tax impact (47% rate in Q1): Surcharge rate change inflated effective tax; full-year should normalize to 25.62%. Underlying PAT stronger than reported.
RM cost masking: Stock-in-transit accounting made RM appear more efficient (28% vs historical 30–33%). Real operational efficiency unclear.
QoQ PAT collapse (−27.9%): Driven by both tax and possible cost absorption. Needs reconciliation next quarter.
The bull-bear debate
How the street is positioned
The market's post-result reaction is the clearest signal. On announcement day (August 7), the stock fell 6.4% with 56.6% delivery volume—indicating real selling, not noise. The decline held through day 5 (−6.25%), a vote that the market saw past the YoY headline and shared management's caution. The stock is now 9.1% off its all-time high of ₹1,691.9, trading at ₹1,537.9, but still up 66.84% off its 52-week low (₹921.8). Technically, RSI is at 70.2 (overbought), suggesting mean-reversion risk if momentum stalls further. On flows: FII ownership ticked down 0.28 percentage points QoQ to 9.26% (Q1 FY27), while DII held flat at 3.23% and promoter ticked up marginally to 42.70%. The FII trim is modest but directional—institutions are not aggressively rotating into the stock. The street's posture: cautiously skeptical, waiting for catalysts (BMW final approval, Q2 acceleration) to prove out.
Ranked risks: what should concern a holder
Sequential momentum stall (QoQ +0.5%, PAT −27.9%)
HighQ1 was weak despite strong comparatives. If Q2–Q4 don't accelerate, FY27 guidance (565±5%) is at risk. Management's refusal to raise despite catalysts suggests they don't expect material acceleration.
Royal Enfield multi-supplier + share confidentiality
Medium–HighRACL's share of RE supply is withheld (competitive sensitivity). If allocation doesn't scale proportionally or another supplier qualifies, share loss is material.
BMW execution (final approval Oct 24 still pending)
MediumPilot supplies in progress, but final approval not yet confirmed. Delay or demand softening could impact ramp trajectory.
High capex cycle (14.6% of revenue annually)
Medium₹77.4 Cr in FY27 constrains free cash flow. As RE and BMW ramp, working capital needs rise; debt management critical.
Customer concentration (top 29 customers = 100% base; no single >20%)
MediumLoss of a top-5 customer (BMW, RE, KTM, ZF) would be material. RACL sole-sources on BMW/KTM but multi-sources everywhere else.
What to watch next
1 · Q2 revenue run-rate and sequential acceleration
If Q2 grows >5% sequentially, management is winning on new customer ramps and FY27 565±5% Cr guidance will hold comfortably. If Q2 is again flat or negative, FY27 becomes at risk and management's caution is vindicated (catalysts are further out).
2 · BMW final approval and ramp trajectory (Oct 24 decision)
October 24 is the formal sign-off for Project Venus. Watch the next call for any delays or demand signals from customer acceptance. Pilot shipments should yield feedback on production readiness.
3 · Royal Enfield volume and share clarity (next two quarters)
Management withheld RACL's % share of RE supply, citing competitive sensitivity. Watch whether RE is scaling above 8K/month toward 10K nomination and whether RACL is holding or gaining share. This is the single biggest domestic upside case.
The honest read
RACL delivered a steady quarter, not a step-change. Strong year-over-year growth (31.5%) is real and reflects the quality of the franchise, but it masks a sequential stall (0.5%) and profit decline (−27.9% QoQ) that are equally real. Management's catalysts—BMW, Royal Enfield, KTM recovery—are material and progressing, but they are not expected to move the needle materially in FY27. The company is positioning for an inflection in FY28+ rather than claiming acceleration now.
The stock's post-result selloff (−6.4% day 1, −6.25% day 5) correctly reflected this reality. At ₹1,537.9, down 9.1% from its all-time high but still 66.84% above its 52-week low, the stock is fairly positioned: priced for steady state, not excitement.
The number to track from here is Q2 sequential revenue growth. If it exceeds 5%, catalysts are accelerating and the FY27 guide is a floor. If it's again flat, management's caution is the more honest signal, and the market should price for FY28 upside rather than FY27.